Skip to content
PreclinicalResearch compound

Pyrilutamide

Experimental scalp compound for hair loss (KX-826); not proven in humans and not approved anywhere.

Available at
MINOXIDILMAX logo
MINOXIDILMAXProduct page

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Pyrilutamide vial

DETAILED OVERVIEW

What is Pyrilutamide?

Pyrilutamide (KX-826) is an experimental compound for hair loss, applied to the scalp, developed by a company called Kintor Pharmaceutical. It is mainly being studied for hormone-related hair thinning (androgenetic alopecia), in both men and women. It is not approved anywhere and can only be used in clinical trials.

It stops DHT (dihydrotestosterone, a strong male hormone) from acting on hair follicle cells, so in principle it may slow the gradual shrinking of the follicles. Because it works locally, in principle it should not cause the side effects of anti-hormone drugs that act on the whole body. It is not proven to work in humans: clinical trials are under way, but there are still few efficacy results published in scientific journals. In the trials, mild redness, itching, flaking and dryness occurred on the scalp, but long-term safety is not known. It is to be avoided in pregnancy, because as a male-hormone blocker it could in principle harm the development of a male baby.

Development code

KX-826 (Kintor Pharmaceutical)

Status

Clinical trials (phase 2/3, hair loss); not approved anywhere

Mechanism of action

Topical androgen-receptor antagonist (local anti-DHT)

Form studied

Topical solution (e.g. 0.5% / 1.0%, 1-2x daily)

Evidence

Early/mid-phase; published efficacy still lacking

Data console

Lab data

Classification-
StructureN/A
Molecular weightN/A
Target area-
Storage2–8°C
Stability~30 days reconstituted

Safety

Side effects, stop signs, contraindications

Side effects · 3

  • Local scalp reactions: in the trials the most common are mild application-site erythema, itching, flaking or dryness; usually mild and transient.
  • Limited long-term safety data: as the compound is INVESTIGATIONAL (phase 2/3), the long-term safety profile is not yet complete; peer-reviewed published data are sparse.
  • Systemic antiandrogen effect minimized by design: the intended advantage is LOCAL action (low systemic absorption), but the full human safety picture awaits ongoing trials.

Contraindications · 3

  • Not an approved drug, investigational: routine use outside a clinical trial is not advised – there is no approved therapeutic indication.
  • Pregnancy and childbearing potential without precautions: as an androgen-receptor antagonist it may pose a theoretical risk to male fetal development; avoid in pregnancy.
  • Broken, inflamed scalp; known hypersensitivity to the active or the vehicle.

Related Hair & Skin

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about Pyrilutamide?

Educational hair and skin info from official sources (PubMed, FDA, EMA). Does NOT replace medical consultation. Talk to a dermatologist!

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.